Concepedia

Armanini Mark

AM

Statistics

Publications

1

Citations

10

H-Index

1

Active since

2019

Affiliations

Takeda (United States)(Current)

Armanini Mark is an author at Takeda (United States).

Publications per year

2019–2019

1

Publications

1

TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo

Marjan Fatholahi, Armanini Mark, Mingying Bi et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 10 citations

1–1 of 1